Biocon's First US Manufacturing Facility
Sector: Warehouse • Location: Cranbury, New Jersey, United States
Source: The Economic Times
Biocon Ltd inaugurated its first manufacturing facility in the US, located in Cranbury, New Jersey, operated by its subsidiary Biocon Generics Inc. The facility was established following the acquisition of the Oral Solid Dosage facility from Eywa Pharma Inc in 2023, with an investment of over USD 30 million. The plant has an annual production capacity of 2 billion tablets and has already commercia
- Status
- Closed
- Sector
- Warehouse, Manufacturing (Industrial)
- Location
- Cranbury, New Jersey, United States of America
- Updated
- 22 Jul 2026
- Source
- The Economic Times
ConstructChat
Ask ConstructChat about Biocon's First US Manufacturing Facility
Pick a question to edit it, or write your own.
First answer free · no account
Project Information FAQ
Project Information
Participants
| Not available for this record. |
Status
Original status | completed |
Taiyo status | Closed |
Taiyo last update | 2026-07-22 |
Contact
| Not available for this record. |
Description
Description | Biocon Ltd inaugurated its first manufacturing facility in the US, located in Cranbury, New Jersey, operated by its subsidiary Biocon Generics Inc. The facility was established following the acquisition of the Oral Solid Dosage facility from Eywa Pharma Inc in 2023, with an investment of over USD 30 million. The plant has an annual production capacity of 2 billion tablets and has already commercialized some products, with more in the pipeline. This investment aims to diversify Biocon's manufacturing base, strengthen its supply chain, and expand its global footprint. |
Original sector | Healthcare/Biotech |
Budget |
Location
Country | United States of America (USA) |
State | New Jersey |
City | Cranbury |
Source
Source | The Economic Times |
URL |
More Details
Record type | Project |
Sector | Warehouse, Manufacturing (Industrial) |
Article published date | 2025-09-16 |
Research
Free account
View all details
You are reading the public part. A free account opens the rest:
- Every detail on this project
- News and media coverage
- Technical research
Free account · no card · lands you back on this project